Aref Al-Kali

Comparison of different models in #CCUS ⭐️ models perform differently based on endpoint ⭐️ CCRS/CHRS do well for progression to MN ⭐️ models perform differently to predict MDS vs CMML vs AML ⭐️ to predict OS modified IPSS-m did the best ⁦#ccus pubmed.ncbi.nlm.nih.gov/41738526/

A new chapter is starting soon for these young researchers. Congrats @MHDSheikhNajeeb and #AhmadShaban for moving to #InternalMedicineResidency. You helped and learnt about #myeloid_research. @MayoCancerCare #Cancer_research

Landmark day for treating newly diagnosed AML First all oral drugs for inducing and maintaining remission in unfit #AML ⭐️ benefits: less travel to clinic to receive these drugs ⭐️ concerns: potential higher cost to healthcare system #FDA #amlsm fda.gov/drugs/resource…

FDA’s Project Facilitate offers free support for community providers, ensuring ALL patients with cancer can access investigational treatments — regardless of where they’re treated. 🔗Learn more: fda.gov/about-fda/onco…

@eaonc @olisaogbue @MrinalPatnaik @AntoineNSaliba @tariqkewan @MayoCancerCare @MayoHemeOnc 🎉 congrats 👏

@olisaogbue @MrinalPatnaik @AlkaliDr @AntoineNSaliba @tariqkewan @MayoCancerCare @MayoHemeOnc Congratulations! 👏

I’m deeply honored to receive the 2026 #EAOnc Paul Carbone, MD Fellowship Award. Thankful to my mentors at Mayo Clinic for their guidance, encouragement, and investment in my development @MrinalPatnaik @AlkaliDr @AntoineNSaliba @tariqkewan @MayoCancerCare @MayoHemeOnc @eaonc

@islamsadek18 @yasminabaza1 Congrats!

I’m happy and excited to share that I have joined Takeda as Vice President and Head of US Medical Affairs, Oncology Business Unit. I’m truly grateful to the Oncology Business Unit leadership for the opportunity and for the warm welcome from the US and Global cross-functional teams. I look forward to partnering closely with a high‑performing, mission‑driven organization to help shape an exciting future and advance a strong and innovative oncology portfolio—always with patients at the center of everything we do. Honored to be part Takeda journey #newjob #oncology #science #medicalaffairs #clinicaltrials #leadership #launch #medicalimpact

Our findings support earlier recognition of AML-associated HLH and suggest a potential biologic link between genomic instability and hyperinflammation. Huge thanks to all collaborators across Mayo Clinic! @AntoineNSaliba @AlkaliDr @MayoHemeOnc @MayoClinic

👏 👏 for #FDA ⁦for being prompt with such breakthrough medication #fight_cancer share.google/sAEbHMGQuDMX8u…

Outcome of CD19 CART after blina exposure in rrALL ⭐️ regardless of Blina response, cart ORR similar 👉 Blina non responders had ⬇️ OS when given CART after blina #allsm ashpublications.org/blood/article/…

Interesting findings from colleagues. IPSS-m impact on #MDS and #HCH ⭐️ imps-m pre Transplant does not offer more prognostic benefit than ipss-m at Diagnosis ⭐️ worsening ipss-m pre Transplant has negative impact #mdssm ⁦@BloodAdvances⁩ ashpublications.org/bloodadvances/…

As our knowledge of the pathophysiology of vascular malformations expands, treatment approaches have broadened to include specific targeted therapies based on genetic profiling, with clinical trials ongoing. Read now: ow.ly/ENBu50YKtkF

Molecular grouping of pts treated with #CPX351 vs #7+3 ⭐️ randomised study in #AML_mrc ⭐️ benefit for CPX mainly in AML-mr but not p53m or other cases ⭐️DDD41 did well c CPX but small N ⭐️benefit HCT mainly in aml-mr ⁦@BloodAdvances⁩ ashpublications.org/bloodadvances/…

Neg P3 study adding #dasatinib in CBF+ AML. ⭐️ no change in response or survival ⭐️ AEs ⬆️ in Dasatinib arm #amlsm @BloodPortfolio ashpublications.org/blood/article/…

Our newest paper on association between early neutropenia and thrombocytopenia with subsequent clinical response to imetelstat in lower risk #MDSsm nature.com/articles/s4140…

Division of #hematology #Bash party 🎉 🎈

@MayoHemeOnc @BrJHaem @yazan98j 👉👉 Table with 💎 💎

Comparison of different models in #CCUS ⭐️ models perform differently based on endpoint ⭐️ CCRS/CHRS do well for progression to MN ⭐️ models perform differently to predict MDS vs CMML vs AML ⭐️ to predict OS modified IPSS-m did the best ⁦#ccus pubmed.ncbi.nlm.nih.gov/41738526/

In proliferative #CMML controlling wbc and monocytes is predictive. ⭐️⬇️wbc and ⬇️ AMC predicts ⬆️OS. ⭐️ true in DAC and HU #cmmlsm ⁦@LeukemiaJnl⁩ nature.com/articles/s4137…

Final results of #RELAZA2 trial AML/MDS post alloHCT Rising PCR or decreasing chimerism 👉 AZA-7 was successfully 63% 👉 52% maintained response 👉 25% had long-lasting response ashpublications.org/blood/article/…